pharmacokinetic

Related by string. pharmacokinetics * * pharmacokinetics PK . pharmacokinetic PK . favorable pharmacokinetic profile . safety tolerability pharmacokinetics . pharmacokinetic parameters . safety tolerability pharmacokinetic . tolerability pharmacokinetics . pharmacokinetic profile . pharmacokinetic properties . pharmacokinetic studies . pharmacokinetic profiles *

Related by context. All words. (Click for frequent words.) 81 pharmacokinetics 73 tolerability 72 pharmacodynamics 72 immunogenicity 72 pharmacokinetic profile 71 pharmacodynamic 70 pharmacokinetic studies 69 pharmacokinetics PK 69 pharmacodynamic PD 69 Pharmacokinetic 68 pharmacokinetic PK 67 pharmacokinetic pharmacodynamic 66 pharmacokinetic profiles 66 tolerability profile 66 safety tolerability pharmacokinetic 66 safety tolerability 66 Phase IIa 65 Phase Ib 65 preclinical efficacy 65 pharmacokinetics pharmacodynamics 65 pharmacodynamic effects 65 Phase Ib clinical 65 Phase IIa trial 65 pharmacokinetic parameters 65 multiple ascending dose 65 dose escalation study 65 ascending doses 64 Phase IIa clinical 64 single ascending dose 64 clinical trial 64 efficacy 64 pharmacodynamic profile 64 pharmacokinetic properties 64 oral bioavailability 64 safety tolerability pharmacokinetics 64 Phase 2b study 64 preclinical studies 63 Phase 1b 63 Phase 1b trial 63 Phase Ia 63 Phase 1a 63 Phase III clinical 63 phase Ib 63 dose escalation 63 phase IIa 63 Phase 2a clinical 63 preclinical 63 Phase 2a trial 62 dose escalation trial 62 favorable pharmacokinetic profile 62 PK PD 62 double blind placebo 62 viral kinetic 62 Phase Ib study 62 anti leukemic 62 viral kinetics 62 analgesic efficacy 62 pharmacokinetic PK profile 62 maximally tolerated dose 62 antiviral activity 62 pharmacodynamic properties 62 RDEA# 62 biodistribution 62 PRTX 62 pharmacokinetic characteristics 61 dosing regimens 61 pharmacodynamics PD 61 phase 2a 61 placebo controlled 61 Phase 2b trial 61 ascending dose 61 Phase IIb 61 pharmacokinetic PK study 61 CYT# 61 teduglutide 61 GAMMAGARD 61 INCB# [001] 61 nonclinical studies 61 Phase 1a clinical 61 Phase 2a 60 Phase 2b clinical 60 ISIS # 60 thorough QT 60 ganetespib 60 Pharmacokinetic PK 60 Azedra 60 dose cohorts 60 Phase 1b clinical 60 rHuPH# 60 dose proportionality 60 dosing 60 Phase Ib II 60 ORMD 60 tolerability profiles 60 multicenter Phase II 60 dose escalation clinical 60 PS# [001] 59 Marqibo 59 antiviral efficacy 59 plasma pharmacokinetics 59 clinical pharmacology studies 59 active comparator 59 vivo 59 phase IIa clinical 59 PXD# 59 tanespimycin 59 bioequivalence 59 GLP toxicology studies 59 Phase #b/#a 59 Phase III trials 59 orally bioavailable 59 intermittent dosing 59 teriflunomide 59 Phase IIB 59 efficacy tolerability 59 subcutaneously administered 59 fosbretabulin 59 pivotal Phase III 59 galiximab 59 enzastaurin 59 ataluren 59 antitumor activity 59 randomized placebo controlled 59 Phase IIIb clinical 59 clinical trials 59 Sym# 59 Phase III 59 NGX# 59 phase IIb 59 HGS ETR1 58 favorable pharmacokinetic 58 Triolex 58 Androxal TM 58 lintuzumab 58 mg dose 58 efficacy endpoints 58 ritonavir boosting 58 BNC# 58 KRN# 58 GRN#L 58 Cloretazine R VNP#M 58 desvenlafaxine succinate 58 oral prodrug 58 varespladib 58 Phase IIb clinical 58 pharmacodynamic parameters 58 crizotinib PF # 58 preclinically 58 pivotal Phase 58 randomized double 58 IDX# 58 placebo controlled clinical 58 LT NS# 58 Blinatumomab 58 oral rivaroxaban 58 rALLy trial 58 vitro experiments 58 cannabinor 58 Pharmacokinetics 58 Dacogen injection 58 dosage regimens 58 Phase Ib clinical trials 58 posaconazole 58 CANCIDAS 58 Kahalalide F 57 pharmacodynamic markers 57 Phase IIb III 57 bioavailability 57 antiviral potency 57 tolerability pharmacokinetics 57 Carfilzomib 57 Pharmacokinetics PK 57 dose limiting toxicities 57 preclinical pharmacokinetic 57 TRV# [001] 57 S/GSK# 57 PMX # 57 favorable tolerability 57 Phase 2b 57 Phase III clinical trials 57 GFT# 57 secondary efficacy endpoints 57 CK # 57 ADAGIO study 57 phase IIb clinical 57 subcutaneous formulation 57 tolerated dose MTD 57 Phase IIb trial 57 ganaxolone 57 systemically administered 57 RE SURGE 57 potent antiviral 57 prucalopride 57 pomalidomide 57 placebo controlled clinical trials 57 Valortim ® 57 TMC# [002] 57 Phase #/#a 57 fluticasone furoate 57 ritonavir boosted 57 R#/MEM # 57 DAVANAT 57 pharmacodynamic profiles 57 RG# [001] 57 LEP ETU 57 PSN# [002] 57 double blinded randomized 57 retapamulin 57 PF # [001] 57 MGCD# [001] 57 MIRCERA 57 placebo controlled Phase 57 diabetic neuropathic pain 57 #mg dose [001] 57 BAL# [002] 57 vidofludimus 57 pharmacodynamic endpoints 57 Phase 2b clinical trials 57 riociguat 57 Secondary endpoints 57 administered subcutaneously 57 obatoclax 56 CG# [003] 56 subcutaneous SC 56 nitazoxanide 56 Preclinical studies 56 ADX# 56 ON #.Na 56 oral dosing 56 APTIVUS 56 pharmacodynamic PK PD 56 dose escalation Phase 56 celgosivir 56 trodusquemine 56 NOX E# 56 mapatumumab 56 Phase #b/#a trial 56 urocortin 2 56 hGH CTP 56 MERLIN TIMI 56 dose cohort 56 rBChE 56 Cloretazine 56 AZILECT R 56 LCP AtorFen 56 JAK inhibitor 56 ADVANCE PD 56 perifosine 56 LEVADEX 56 pitavastatin 56 Plicera 56 MAP# 56 HspE7 56 CRLX# 56 HGS ETR2 56 CLORETAZINE TM VNP#M 56 MGd 56 GLYX 56 Traficet EN 56 Panzem R NCD 56 dosing regimen 56 highly immunogenic 56 multicenter randomized placebo controlled 56 Archexin 56 arbaclofen 56 blinded randomized placebo controlled 56 coadministration 56 NEUGENE antisense 56 polymerase inhibitor 56 nonrandomized 56 lanthanum carbonate 56 Alocrest 56 XmAb# 56 davunetide intranasal AL 56 intravenous dosing 56 neratinib 56 bendamustine 56 ProLindac 56 decitabine 56 TPI ASM8 56 EOquin 56 vicriviroc 56 Aclidinium 56 orally dosed 56 imetelstat 56 NP2 Enkephalin 56 DermaVir Patch 56 LEXIVA r 56 peripheral blood mononuclear 56 rFIXFc 56 tasimelteon 56 alvespimycin 56 pharmacologic 56 Phase IIa trials 56 eculizumab 56 randomized Phase 2b 56 vivo efficacy 56 randomized multicenter 56 CELVAPAN H#N# 56 Apoptone 56 Pharmacokinetic studies 56 dosing cohort 56 clinically meaningful 55 APTIVUS r 55 phase IIb study 55 torezolid phosphate 55 TOLAMBA 55 elacytarabine 55 virological response 55 PCK# 55 receptor inhibitor 55 eniluracil 55 GHRH 55 vivo preclinical 55 Antiviral Activity 55 vitro studies 55 ILLUMINATE 55 LibiGel Phase III 55 intravesical 55 eltrombopag 55 IMGN# 55 BAY #-# 55 bicifadine 55 GLP toxicology 55 GAP #B# 55 ENMD # 55 CoFactor 55 ruxolitinib 55 lomitapide 55 Onconase 55 achieved statistical significance 55 Capesaris 55 blinded randomized 55 AEG# 55 placebo controlled Phase III 55 blinatumomab 55 PEGPH# 55 Xanafide 55 Pharmacodynamic 55 AEGR 55 Omacetaxine 55 Secondary endpoints include 55 randomized Phase III 55 Zoraxel 55 ELACYT 55 Phase III psoriasis 55 preclinical toxicology 55 SPIRIVA HandiHaler 55 dose dose escalation 55 JAK2 inhibitors 55 VNP#M 55 melphalan prednisone 55 surrogate endpoint 55 QLT# 55 AVN# [001] 55 genotypic 55 Onrigin 55 budesonide MMX 55 investigational 55 solithromycin 55 azacitidine 55 PEG Interferon lambda 55 multicentre randomized 55 placebo controlled randomized 55 clinically relevant 55 #ME# 55 pertuzumab 55 isatoribine 55 demonstrated antitumor activity 55 randomized clinical 55 NO# [002] 55 monotherapy 55 Inhalation Solution 55 Phase 2b randomized 55 VA# [002] 55 mcg dose 55 CCR5 antagonist 55 sunitinib malate 55 HIF PH inhibitors 55 dose escalation phase 55 pharmacological 55 blinded placebo controlled 55 elotuzumab 55 registrational 55 DASISION 55 NOXAFIL Oral Suspension 55 Immunogenicity 55 Amigal 55 Aplidin 55 placebo controlled studies 55 Preclinical 55 YONDELIS 55 dose proportional pharmacokinetics 54 COMFORT II 54 SRT# [003] 54 velafermin 54 tezampanel 54 depsipeptide 54 Imprime PGG 54 plasma concentrations 54 vivo toxicology 54 PRT# 54 phase IIb III 54 SCH # 54 RezularTM 54 PD LID 54 oral deforolimus 54 GAMMAGARD LIQUID 54 INCB# [002] 54 CA4P 54 Iloperidone 54 randomized Phase 54 noninferiority 54 Cloretazine R 54 erythropoietic 54 inhibitor RG# 54 bosentan 54 CCX# 54 HGS# 54 carcinogenicity studies 54 Chemophase 54 mecamylamine 54 NXL# 54 TELCYTA 54 uricase 54 GMX# 54 topical formulation 54 Anthim 54 HCV infected 54 RE LY ® 54 indibulin 54 #beta estradiol 54 forodesine 54 vitro cytotoxicity 54 Phenoptin 54 Phase IIb trials 54 MoxDuo IR 54 preclinical models 54 oral FTY# 54 prospectively defined 54 CR# vcMMAE 54 pramlintide metreleptin combination 54 guanfacine extended release 54 evaluating REVLIMID 54 confirmatory Phase III 54 delafloxacin 54 Corlux 54 HCV SPRINT 54 bronchodilation 54 AEZS 54 label dose escalation 54 randomized controlled 54 ARIKACE 54 clinical endpoints 54 nucleotide analog 54 Symadex 54 ORENCIA ® 54 pharmacokinetic equivalence 54 triphendiol 54 rNAPc2 54 ESBA# 54 ALN TTR# 54 AeroLEF TM 54 reactogenicity 54 Debio 54 ongoing Phase 1b 54 Menerba 54 Phase III randomized controlled 54 Elagolix 54 oritavancin 54 ATL# [001] 54 Preclinical studies suggest 54 Plenaxis TM 54 PREZISTA r 54 EOquin TM 54 AZX# 54 dosing cohorts 54 AZILECT 54 oral diclofenac 54 CaPre TM 54 masked placebo controlled 54 tecarfarin 54 PEG PAL 54 miglustat 54 INT# [002] 54 DURATION 54 OHR/AVR# 54 Ophena TM 54 IMC A# 54 ramelteon 54 tumorigenicity 54 glucose lowering 54 DCCR 54 Valortim R 54 retaspimycin 54 C1 INH 54 HuMax CD# 54 placebo controlled dose escalation 54 dose regimen 54 Actilon 54 BRIM3 54 OXi# 54 AVADO 54 dose regimens 54 subgroup analyzes 54 oral formulation 54 EDEMA3 trial 54 glufosfamide 54 Spiegelmer ® 54 clinical 54 CIMZIA TM 54 RSD# 54 antitumor 54 randomized multicenter Phase III 54 pafuramidine 54 adipiplon 54 phase IIIb 54 TG# [001] 54 RSD# oral 54 antidepressant efficacy 54 ISTODAX 54 pramlintide 54 insulin detemir 54 ALGRX 54 intravenously administered 54 dose titration 54 OMP #M# 54 Cimzia ® certolizumab pegol 54 antitumour activity 54 FTY# 54 Elacytarabine 54 multicenter Phase 54 primary endpoint 54 Phase IIIb 54 vismodegib 54 CEQ# 54 tipranavir 54 voreloxin 54 microdose 54 trastuzumab Herceptin ® 54 Tolerability 54 pharmacokinetic interactions 54 Dasatinib 54 BMS# 54 alemtuzumab MS 54 Phase III pivotal 54 telbivudine 54 HuMax EGFr 54 mg kg BID 54 DXL# 54 liposomal formulation 54 xenograft models 54 Bronchitol 53 Phase II 53 Cmax 53 Altastaph 53 mGluR5 NAM 53 Posiphen 53 Tracleer R 53 PROMACTA 53 Increlex ® 53 AMD# [003] 53 IIa trial 53 LEXIVA 53 Dual Opioid 53 LB# [003] 53 rALLy clinical trial 53 TRIOLEX 53 histone deacetylase HDAC inhibitor 53 GATTEX 53 EndoTAG TM -1 53 phase IIb trial 53 Alpharadin 53 IFN Beta 53 secretin 53 pramipexole 53 tacrolimus ointment 53 TMC# C# 53 multicenter 53 RGB # 53 milatuzumab 53 low dose cytarabine 53 TACI Ig 53 EGS# 53 protease inhibitor PI 53 orally administered 53 randomized controlled clinical 53 Valortim 53 Initiated Phase 53 Tyrima 53 ZYBRESTAT 53 randomized 53 CBLB# 53 CTA# 53 blind randomized placebo 53 hemostatic efficacy 53 NLX P# 53 MoxDuo 53 afamelanotide 53 randomized clinical trials 53 Interferon alpha 53 radezolid 53 alagebrium 53 blind placebo 53 #th Annual Interscience 53 GSK# [001] 53 immunological responses 53 Prosaptide 53 novel VDA molecule 53 sunitinib 53 perifosine KRX 53 ceftazidime 53 Valdoxan 53 ProSavin 53 nab paclitaxel 53 Phase IIIb study 53 PROPEL trial 53 OncoVEX GM CSF 53 double blinded placebo 53 Secondary efficacy endpoints 53 masitinib 53 RoACTEMRA 53 mertansine 53 insulin lispro 53 Onbrez Breezhaler 53 resolvin 53 HCV polymerase inhibitor 53 subcutaneous injections 53 lisdexamfetamine dimesylate 53 Phase IIb clinical trials 53 active moiety 53 vorinostat 53 ANA# 53 MoxDuo ® IR 53 axitinib 53 evaluable patients 53 omega interferon 53 Omacetaxine mepesuccinate 53 seliciclib 53 unblinded 53 insulin degludec 53 eszopiclone 53 Pharmacokinetic parameters 53 docetaxel 53 huC# DM4 53 elvitegravir 53 partial agonist 53 Enhanze Technology 53 Androxal 53 inecalcitol 53 Multimeric 53 dirucotide 53 BETAS 53 naproxcinod 53 radiation dosimetry 53 Spheramine 53 GLPG# 53 PRX# 53 Triapine R 53 Prodarsan ® 53 secondary endpoints 53 NN# [001] 53 dasatinib 53 MNTX 53 Annamycin 53 MEK inhibitor 53 Tamibarotene 53 carcinogenicity study 53 prospective randomized controlled 53 AQ4N 53 ALTU 53 IIa clinical 53 SUTENT ® 53 BCX# 53 AVE# 53 clevidipine 53 APD# 53 Zenvia 53 EFAPROXYN 53 bevirimat 53 confirmatory clinical 53 JVRS 53 randomized blinded 53 EXPAREL ™ 53 TAXUS VI 53 ALKS 53 administered orally 53 antifibrotic 53 hemagglutination inhibition HAI 53 azficel T 53 inhaled iloprost 53 paclitaxel poliglumex 53 mesalamine granules 53 BAL# [001] 53 CDK inhibitor 53 Amrubicin 53 rhGH 53 LAF# 53 atazanavir ritonavir 53 VAPRISOL 53 RRMS patients 53 UPLYSO 53 HuMax CD4 53 brivaracetam 53 CBLC# 53 Phase 1b clinical trials 53 vinorelbine 53 ibudilast 53 APOPTONE 53 ancrod 53 KNS # 53 picoplatin 53 alvimopan 53 investigational drug 53 Phase #/#a clinical 53 eprotirome 53 Zerenex 53 stated Michelle Berrey 53 trials RCTs 53 optimal dosing 53 mg doses 53 REMINYL ® 53 investigational compound 53 selective modulator 53 visilizumab 53 HIF PHI 53 rotigotine 53 trabectedin 53 5 FU 53 USL# 53 clofarabine 53 Relivar 53 Phase III Clinical Trials 53 RH1 53 oral iron chelator 53 Zavesca R 53 busulfan 53 oral antiviral 53 OncoVEX 53 PEG SN# 53 IRX 2 53 CORT # 53 ZYBRESTAT fosbretabulin 53 urate lowering 53 AP# [003] 53 RE LY trial 53 statistically significant efficacy 53 ANAVEX #-# [003] 53 temozolomide 53 avosentan 53 DLTs 53 INTERCEPT platelets 53 cariprazine 53 demonstrated statistically significant 53 calcitonin 53 efavirenz EFV 53 multicenter randomized controlled 53 Ostarine 53 tezampanel NGX# 52 TRO# 52 MabCampath 52 AZD# 52 non inferiority 52 midstage trials 52 interferon gamma 1b 52 Protelos 52 REYATAZ R 52 guanfacine 52 randomized crossover 52 Panzem R 52 Exelixis compounds 52 intranasal formulation 52 GLP1 agonist 52 prospective multicentre 52 teriparatide 52 SPIRIT III 52 Zybrestat 52 veltuzumab 52 sapacitabine 52 Campath alemtuzumab 52 multicenter clinical 52 patients evaluable 52 alemtuzumab Campath 52 MyVax R 52 apremilast 52 DAS# [001] 52 Fx #A 52 Phase IIA 52 REVLIMID lenalidomide 52 SILENOR TM 52 Trofex 52 relapsed MM 52 FOSRENOL ® 52 TMC# [001] 52 efficacy endpoint 52 glatiramer acetate 52 FOLOTYN ® 52 subanalysis 52 maturation inhibitor 52 investigational protease inhibitor 52 CRx 52 clinical trials Multikine 52 Phase III placebo controlled 52 AZILECT ® 52 prokinetic agent 52 mg/m2 cohort 52 MBP# [001] 52 histone deacetylase inhibitor 52 omecamtiv mecarbil 52 non nucleoside 52 preclinical pharmacology 52 CIMZIA TM certolizumab pegol 52 BRIM2 52 ALB # 52 HCV RESPOND 2 52 safinamide 52 IND enabling 52 Proellex TM 52 PREOS 52 Taxotere ® 52 PDE4 inhibitor 52 INC# 52 mg kg dose 52 avanafil 52 Cloretazine ® 52 Solulin 52 LY# [003] 52 blind randomized 52 randomized multicenter trial 52 vitro 52 SYMMETRY trial 52 peginesatide 52 Clolar 52 Denufosol 52 Enzastaurin 52 LUNESTA 52 sulodexide 52 tocilizumab 52 oral methylnaltrexone 52 GetGoal Phase III 52 pharmacokinetic pharmacodynamic PK PD 52 LCP Tacro 52 AIR# [001] 52 Tarceva TM 52 Teriflunomide 52 aclidinium 52 Milnacipran 52 XL# [003] 52 Genz # 52 neuroprotective properties 52 dasatinib Sprycel 52 systemic absorption 52 Zenvia Phase III 52 Anticalins 52 enfuvirtide 52 heavily pretreated 52 SAR# [004] 52 relapsed refractory 52 enoximone 52 Clonicel 52 EVIZON 52 intranasal delivery 52 ofatumumab 52 SNT MC# 52 oral ibandronate 52 alpha 2a 52 nucleoside analog 52 blind placebo controlled 52 zonisamide SR 52 Pivotal Phase III 52 daily subcutaneous injections 52 subcutaneous dosing 52 Onrigin TM 52 Primary endpoints 52 topically administered 52 telaprevir dosing 52 thymalfasin 52 Laquinimod 52 cobiprostone 52 IFN alpha 52 ATL/TV# 52 IPLEX 52 metabolite identification 52 ritonavir boosted protease inhibitor 52 DP b# 52 CRMD# 52 PYY3 52 PROCHYMAL 52 primary endpoints 52 CLL8 52 PPAR gamma agonist 52 anticancer activity 52 Allovectin 7 ® 52 bolus injection 52 Reolysin 52 NEBIDO 52 eliglustat tartrate 52 immunological 52 Aryplase 52 novel prodrug 52 tolevamer 52 caspofungin 52 trastuzumab emtansine T DM1 52 Perifosine 52 antitumor effect 52 APPRAISE 52 oral COTI 52 μg kg 52 methylnaltrexone 52 Synavive 52 CLARITY study 52 immunomodulator 52 alicaforsen enema 52 Tarvacin TM 52 Exherin TM 52 #mg/day [001] 52 human microdosing 52 PLX PAD 52 flavopiridol 52 quadrivalent HPV vaccine 52 PTH analogue 52 Phase III randomized 52 VP# [004] 52 peginterferon alfa 2b 52 Hyphanox 52 deforolimus 52 serum cortisol 52 Azixa 52 oxymorphone ER 52 dacetuzumab 52 tipifarnib 52 MLN# 52 IAP inhibitor 52 RHUCIN 52 Vilazodone 52 KB# [002] 52 cathepsin K inhibitor 52 multicenter randomized Phase 52 trastuzumab DM1 T DM1 52 virologic 52 vernakalant hydrochloride 52 EDEMA3 52 wilate ® 52 PEARL SC 52 immunomodulatory effects 52 HCD# [002] 52 Engerix B 52 Medidur TM FA 52 BrachySil TM 52 TNFalpha 52 SABCS 52 ASSERT trial 52 Panzem 52 docetaxel Taxotere R 52 L PPDS 52 TRANSFORMS 52 liprotamase 52 Phase #/#a trial 52 ISENTRESS 52 fosamprenavir 52 Aplidin R 52 NOXAFIL 52 bovine thrombin 52 BrachySil 52 serologic 52 TG# [003] 52 H#N# VLP vaccine 52 selective androgen receptor modulator 52 Fludara 52 PEG IFN 52 Dosing 52 Fulvestrant 52 Serdaxin 52 bortezomib Velcade 52 BioVant 52 Vidaza 52 Nasulin 52 antiangiogenic therapy 52 sitagliptin 52 serum lipid 52 MGCD# [002] 52 Safinamide 52 mg/m2 dose 52 primary efficacy endpoints 52 linear pharmacokinetics 52 selegiline 52 LAB CGRP 52 multicenter randomized 52 Forodesine HCl 52 evaluable 52 bifeprunox 52 AVERROES 52 Arikace 52 nucleoside 52 PrevOnco ™ 52 ALISTA 52 COPAXONE R 52 bioequivalence studies 52 budesonide foam

Back to home page